eligibility_summary
Adults 18–75 with histologically confirmed unresectable/recurrent/metastatic solid tumors, ≥1 RECIST v1.1 target lesion, ECOG 0–1, life expectancy >12 wks, using contraception, women non‑pregnant, consented. Exclude prior MET‑targeted therapy or EGFR mAbs/bispecifics, recent systemic therapy (≤2 wks), investigational drugs/ADCs (≤4 wks), RT (≤2 wks or extensive ≤4 wks), effusions/pericardial, major surgery (≤4 wks), unresolved ≥G2 toxicities, active second cancer, untreated/active CNS mets, severe CV disease, serious infection (≤4 wks).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06621563 (Phase Ib, recruiting): Tests HS-20117 combinations in advanced solid tumors (NSCLC, CRC). Drugs/interventions and mechanisms: • HS-20117: fully human IgG1-like bispecific monoclonal antibody targeting EGFR and MET, designed for dual receptor blockade of EGFR/MET signaling and potential Fc-mediated effector functions. • HS-20093: B7-H3–targeting antibody-drug conjugate, binds B7-H3 on tumor cells to deliver a cytotoxic payload. • Chemotherapy backbones: cisplatin/carboplatin (DNA crosslinkers), pemetrexed (antifolate), oxaliplatin (DNA crosslinker), capecitabine/5-FU (pyrimidine analogs, thymidylate synthase inhibition), irinotecan (topoisomerase I inhibitor), leucovorin (enhances 5-FU). Targeted cells/pathways: EGFR- and MET-driven tumor signaling, B7-H3–expressing tumor cells, DNA synthesis/repair and topoisomerase pathways. Populations: NSCLC with EGFR exon 20 insertions or classical mutations, RAS/BRAF V600E–WT CRC.